Nayla Chaijale
Overview
Explore the profile of Nayla Chaijale including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
24
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frank S, Testa C, Goldstein J, Kayson E, Leavitt B, Oakes D, et al.
CNS Drugs
. 2025 Jan;
39(2):185-195.
PMID: 39825184
Background: Huntington disease (HD) is a progressive neurodegenerative disease that causes psychiatric and neurological symptoms, including involuntary and irregular muscle movements (chorea). Chorea can disrupt activities of daily living, pose...
2.
Frank S, Anderson K, Fernandez H, Hauser R, Claassen D, Stamler D, et al.
Neurol Ther
. 2024 Sep;
13(6):1747-1749.
PMID: 39266813
No abstract available.
3.
Hauser R, Barkay H, Fernandez H, Jimenez-Shahed J, Factor S, Gross N, et al.
J Clin Psychopharmacol
. 2024 Jun;
44(4):386-396.
PMID: 38901008
Background: Deutetrabenazine is approved for adults with tardive dyskinesia (TD). Data based on underlying psychiatric condition and baseline dopamine receptor antagonist (DRA) use are limited. Methods: Patients with TD who...
4.
Frank S, Anderson K, Fernandez H, Hauser R, Claassen D, Stamler D, et al.
Neurol Ther
. 2024 Apr;
13(3):655-675.
PMID: 38557959
Introduction: Deutetrabenazine is a vesicular monoamine transporter 2 inhibitor used to treat tardive dyskinesia (TD) and chorea associated with Huntington disease (HD). To enhance detection of safety signals across individual...
5.
Robinson D, Suett M, Wilhelm A, Chaijale N, Franzenburg K, Gandhi S, et al.
Adv Ther
. 2023 Mar;
40(5):2249-2264.
PMID: 36905498
Introduction: Studies evaluating patient and healthcare professional (HCP) preferences regarding long-acting injectable (LAI) antipsychotic agent attributes are lacking. Methods: Surveys were administered to physicians, nurses, and patients who had at...
6.
Sajatovic M, Finkbeiner S, Wilhelm A, Barkay H, Chaijale N, Gross N, et al.
Am J Geriatr Psychiatry
. 2021 Sep;
30(3):360-371.
PMID: 34511333
Objectives: To assess long-term safety and efficacy of deutetrabenazine in younger (<55 years) and older (≥55 years) adult participants with tardive dyskinesia (TD). Design: Three-year, single-arm, open-label extension (OLE) study...
7.
Ganesh A, Gonzalez-Sulser A, Chaijale N, Cucchiaro G
Eur J Pharmacol
. 2008 Feb;
584(1):93-9.
PMID: 18304527
We evaluated the electrophysiologic response of locus coeruleus neurons to the systemic and local infusion of epibatidine. Rats were anesthetized with 2% halothane and single-unit locus coeruleus discharge was recorded...
8.
Cucchiaro G, Chaijale N, Commons K
Neuropharmacology
. 2006 Feb;
50(7):769-76.
PMID: 16460769
The mechanisms and sites of action of epibatidine-induced antinociception and side effects are poorly understood. The present study tested the hypothesis that the locus coeruleus is a site of action...
9.
Cucchiaro G, Chaijale N, Commons K
J Pharmacol Exp Ther
. 2004 Dec;
313(1):389-94.
PMID: 15608080
The mechanisms and sites of action of epibatidine-induced antinociception and side effects are poorly understood. The present study tested the hypothesis that the serotonergic dorsal raphe nucleus is a site...